Primary tumor response to preoperative chemoradiation with or without oxaliplatin in locally advanced rectal cancer: pathologic results of the STAR-01 randomized phase III trial.
By C. Aschele, L. Cionini, S. Lonardi, C. Pinto, S. Cordio, G. Rosati, S. Artale, A. Tagliagambe, G. Ambrosini, P. Rosetti and 10 more. Journal of Clinical Oncology, 2011
743 citations recorded by the source corpus.
View Paper: https://www.semanticscholar.org/paper/7d98f078e52d7aa49540877b654672ab55f8c1aa
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Oncology
Citations in the corpus
- ESMO Consensus Guidelines for management of patients with colon and rectal cancer. a personalized approach to clinical decision making. (2012, result): “Despite early promising results for 5-FU/oxaliplatin or capecitabine/oxaliplatin, local complete pathological response (pCR) was not increased compared with FU alone in the STAR-01, ACCORD 12/ 0405-Prodige 2, and NSABP R-04 [61–63].”
- Randomized trial of short-course radiotherapy versus long-course chemoradiation comparing rates of local recurrence in patients with T3 rectal cancer: Trans-Tasman Radiation Oncology Group trial 01.04. (2012, positive): “The use of long-course preoperative chemoradiotherapy with different chemotherapeutic and biologic agents has been investigated with the aim of further improving local control and survival.(7,8) Although both short-course preoperative radiotherapy and longcourse preoperative chemoradiotherapy have b”